Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (#01ZX1307, #01ZX1607)
Berlin Institute of Health (TERMINATE-NB CRG04 collaborative research project) and in the TransTumVar project
Received: 23 November 2020
Accepted: 18 October 2021
First Online: 23 November 2021
: The authors declare no competing interests, except for D.G. who is employed by Experimental Pharmacology and Oncology Berlin-Buch GmbH.